EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum
|
EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Dividend The general partner and the supervisory board of CompuGroup Medical SE & Co. KGaA (the „Company“) (ISIN: DE000A288904 | WKN: A28890) intend to propose to the annual general meeting that only the legally required minimum shall be paid out as dividend for the financial year 2024. This would result in a distribution of EUR 0.05 per dividend bearing share (previous year: EUR 1.00), assuming an unchanged amount of treasury shares. The proposal is made against the backdrop of the Company’s long-term innovation and growth strategy, including investments in infrastructure and resources for greater proximity to customers as well as AI-based processes and products. It further considers, based on the prepared consolidated financial statements, the development of revenue and profitability in the financial year 2024 in line with the adjusted full-year forecast. According to the prepared consolidated financial statements, the Company generated revenues of approx. EUR 1.154 billion in the financial year 2024 (previous year: approx. EUR 1.188 billion). The organic revenue decreased by around two per cent year-on-year. Adjusted EBITDA decreased by around 15 per cent to approx. EUR 224.6 million (previous year: approx. EUR 264.8 million). The adjusted earnings per share amounted to approx. EUR 1.27 (previous year: approx. EUR 2.06). A dividend payment based on the final dividend proposal of the general partner and the supervisory board for the financial year 2024 is subject to the approval by the annual general meeting, which is expected to be held in August 2025, as well as further legal requirements. CompuGroup Medical SE & Co. KGaA will publish the full annual report for the financial year 2024 as planned on March 6, 2025. “Adjusted EBITDA” and “adjusted earnings per share” are defined in the annual report for the financial year 2023 on p. 45 et seq. End of Inside Information
04-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2095063 |
| End of Announcement | EQS News Service |
|
|
2095063 04-March-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 745,81 | 837,26 | 1.025,32 | 1.129,74 | 1.187,66 | 1.153,99 | 1.188,00 | |
| EBITDA1,2 | 178,13 | 197,48 | 213,39 | 216,35 | 229,76 | 218,74 | 0,00 | |
| EBITDA-Margin3 | 23,88 | 23,59 | 20,81 | 19,15 | 19,35 | 18,96 | 0,00 | |
| EBIT1,4 | 115,27 | 121,77 | 102,68 | 104,03 | 98,00 | 107,09 | 0,00 | |
| EBIT-Margin5 | 15,46 | 14,54 | 10,01 | 9,21 | 8,25 | 9,28 | 0,00 | |
| Net Profit (Loss)1 | 66,15 | 73,42 | 69,03 | 74,12 | 46,87 | 34,76 | 0,00 | |
| Net-Margin6 | 8,87 | 8,77 | 6,73 | 6,56 | 3,95 | 3,01 | 0,00 | |
| Cashflow1,7 | 110,50 | 149,93 | 165,27 | 145,03 | 179,53 | 128,88 | 0,00 | |
| Earnings per share8 | 1,33 | 1,40 | 1,30 | 1,40 | 0,88 | 0,66 | 1,07 | |
| Dividend per share8 | 0,50 | 0,50 | 0,50 | 0,50 | 1,00 | 0,05 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| CompuGroup Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A28890 | DE000A288904 | SE & Co. KGaA | 1.327,24 Mio € | 04.05.2007 | Halten | 9F299HQG+3H |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 20,25 | 33,87 | 0,60 | 21,50 | 2,06 | 10,30 | 1,15 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,00 | 0,05 | 0,50 | 2,02% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 01.08.2025 | 30.04.2025 | 31.07.2025 | 07.11.2024 | 06.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +2,37% | +6,30% | +13,82% | +14,25% | +37,22% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
